Biosimilars

Safeguarding the Global Supply of Medicines Including Biologics

Safeguarding the Global Supply of Medicines Including Biologics

Today, many critical, life-saving medicines go through a complex global supply chain before ever reaching the patient. USP’s public standards play important roles throughout that supply chain. Learn more.

Share

Congress to Remove Key Safety Component of Imported Medicines

Imported Biologic Medicines

The American drug supply is among the safest in the world, with many protections for consumers and patients.  However, a pending proposal in Congress would remove key protections for all biologic drugs—crucial and lifesaving medicines we take like insulin, human growth hormones, and blood thinners. Learn more. 

Share

Abandoning Quality Standards for Biologic Drugs Jeopardizes Patient Safety

Patient Confidence in Biologic Medicines

Legislation being considered by Congress will remove the requirement that all biologic medicines – drugs such as insulin, vaccines, cancer treatments and other therapies made using living matter – comply with public quality standards of the U.S. Pharmacopeia (USP). This same legislation would also apply to biosimilars. As a result, public confidence in biologics and biosimilars as well as patient safety would be at risk. Learn more.

Share

Pages